Skip to main content
Top
Gepubliceerd in: Journal of Autism and Developmental Disorders 12/2009

01-12-2009 | Original Paper

Open-Label Memantine in Fragile X Syndrome

Auteurs: Craig A. Erickson, Jennifer E. Mullett, Christopher J. McDougle

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 12/2009

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.
Literatuur
go back to reference Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.
go back to reference American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (text revision) (4th ed.). Washington, D.C.: American Psychiatric Association.CrossRef American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (text revision) (4th ed.). Washington, D.C.: American Psychiatric Association.CrossRef
go back to reference Bailey, D. B., Jr., Hatton, D. D., Skinner, M., & Mesibov, G. (2001). Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. Journal of Autism and Developmental Disorders, 31(2), 165–174.CrossRefPubMed Bailey, D. B., Jr., Hatton, D. D., Skinner, M., & Mesibov, G. (2001). Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. Journal of Autism and Developmental Disorders, 31(2), 165–174.CrossRefPubMed
go back to reference Bassell, G. J., & Gross, C. (2008). Reducing glutamate signaling pays off in fragile X. Nature Medicine, 14(3), 249–250.CrossRefPubMed Bassell, G. J., & Gross, C. (2008). Reducing glutamate signaling pays off in fragile X. Nature Medicine, 14(3), 249–250.CrossRefPubMed
go back to reference Bear, M. F. (2005). Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain, and Behavior, 4(6), 393–398.CrossRefPubMed Bear, M. F. (2005). Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain, and Behavior, 4(6), 393–398.CrossRefPubMed
go back to reference Bear, M. F., Dolen, G., Osterweil, E., & Nagarajan, N. (2008). Fragile X: Translation in action. Neuropsychopharmacology, 33(1), 84–87.CrossRefPubMed Bear, M. F., Dolen, G., Osterweil, E., & Nagarajan, N. (2008). Fragile X: Translation in action. Neuropsychopharmacology, 33(1), 84–87.CrossRefPubMed
go back to reference Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370–377.CrossRefPubMed Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370–377.CrossRefPubMed
go back to reference Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46(4), 266–271.CrossRefPubMed Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46(4), 266–271.CrossRefPubMed
go back to reference Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., et al. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. Journal of Child and Adolescent Psychopharmacology, 16(5), 525–540.CrossRefPubMed Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., et al. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. Journal of Child and Adolescent Psychopharmacology, 16(5), 525–540.CrossRefPubMed
go back to reference Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome—present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42–48.CrossRefPubMed Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome—present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42–48.CrossRefPubMed
go back to reference Chez, M. G., Aimonovitch, M., Buchanan, T., Mrazek, S., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19(3), 165–169.PubMed Chez, M. G., Aimonovitch, M., Buchanan, T., Mrazek, S., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19(3), 165–169.PubMed
go back to reference Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.CrossRefPubMed Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.CrossRefPubMed
go back to reference Clifford, S., Dissanayake, C., Bui, Q. M., Huggins, R., Taylor, A. K., & Loesch, D. Z. (2007). Autism spectrum phenotype in males and females with fragile X full mutation and premutation. Journal of Autism and Developmental Disorders, 37(4), 738–747.CrossRefPubMed Clifford, S., Dissanayake, C., Bui, Q. M., Huggins, R., Taylor, A. K., & Loesch, D. Z. (2007). Autism spectrum phenotype in males and females with fragile X full mutation and premutation. Journal of Autism and Developmental Disorders, 37(4), 738–747.CrossRefPubMed
go back to reference Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427–433.CrossRefPubMed Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427–433.CrossRefPubMed
go back to reference Dolen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. Journal of Physiology, 586(6), 1503–1508.CrossRefPubMed Dolen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. Journal of Physiology, 586(6), 1503–1508.CrossRefPubMed
go back to reference DuPaul, G., Power, T., Anastopaulus, A., & Reid, R. (1998). ADHD rating scale IV: Checklists, norms, and clinical interpretation. New York: Guilford. DuPaul, G., Power, T., Anastopaulus, A., & Reid, R. (1998). ADHD rating scale IV: Checklists, norms, and clinical interpretation. New York: Guilford.
go back to reference Erickson, C. A., & Chambers, J. E. (2006). Memantine for disruptive behavior in autistic disorder. Journal of Clinical Psychiatry, 67(6), 1000.PubMedCrossRef Erickson, C. A., & Chambers, J. E. (2006). Memantine for disruptive behavior in autistic disorder. Journal of Clinical Psychiatry, 67(6), 1000.PubMedCrossRef
go back to reference Erickson, C. A., Posey, D. J., Stigler, K. A., Mullett, J., Katschke, A. R., & McDougle, C. J. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 191(1), 141–147.CrossRef Erickson, C. A., Posey, D. J., Stigler, K. A., Mullett, J., Katschke, A. R., & McDougle, C. J. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 191(1), 141–147.CrossRef
go back to reference Evans, S. M., Levin, F. R., Brooks, D. J., & Garawi, F. (2007). A pilot double-blind treatment trial of memantine for alcohol dependence. Alcoholism, Clinical and Experimental Research, 31(5), 775–782.CrossRefPubMed Evans, S. M., Levin, F. R., Brooks, D. J., & Garawi, F. (2007). A pilot double-blind treatment trial of memantine for alcohol dependence. Alcoholism, Clinical and Experimental Research, 31(5), 775–782.CrossRefPubMed
go back to reference Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., et al. (2007). A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Journal of Child and Adolescent Psychopharmacology, 17(1), 19–33.CrossRefPubMed Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., et al. (2007). A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Journal of Child and Adolescent Psychopharmacology, 17(1), 19–33.CrossRefPubMed
go back to reference Florencia, G., Irene, S., & Veronica, F. (2006). Fragile-X mental retardation: Molecular diagnosis in Argentine patients. Journal of Biochemistry and Molecular Biology, 39(6), 766–773.PubMed Florencia, G., Irene, S., & Veronica, F. (2006). Fragile-X mental retardation: Molecular diagnosis in Argentine patients. Journal of Biochemistry and Molecular Biology, 39(6), 766–773.PubMed
go back to reference Gerard, B., Le Heuzey, M. F., Brunie, G., Lewine, P., Saiag, M. C., Cacheux, V., et al. (1997). Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Annales de Genetique, 40(3), 139–144.PubMed Gerard, B., Le Heuzey, M. F., Brunie, G., Lewine, P., Saiag, M. C., Cacheux, V., et al. (1997). Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Annales de Genetique, 40(3), 139–144.PubMed
go back to reference Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76–338. Rockville, MD: U.S. DHEW, NIMH. Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76–338. Rockville, MD: U.S. DHEW, NIMH.
go back to reference Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7746–7750.CrossRefPubMed Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7746–7750.CrossRefPubMed
go back to reference Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., et al. (2008). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 34(5), 1322–1329.CrossRefPubMed Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., et al. (2008). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 34(5), 1322–1329.CrossRefPubMed
go back to reference Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., et al. (1989). Autism diagnostic observation schedule: A standardized observation of communicative and social behavior. Journal of Autism and Developmental Disorders, 19(2), 185–212.CrossRefPubMed Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., et al. (1989). Autism diagnostic observation schedule: A standardized observation of communicative and social behavior. Journal of Autism and Developmental Disorders, 19(2), 185–212.CrossRefPubMed
go back to reference Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685.CrossRefPubMed Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685.CrossRefPubMed
go back to reference Mobius, H. J., Stoffler, A., & Graham, S. M. (2004). Memantine hydrochloride: Pharmacological and clinical profile. Drugs Today (Barcelona), 40(8), 685–695.CrossRef Mobius, H. J., Stoffler, A., & Graham, S. M. (2004). Memantine hydrochloride: Pharmacological and clinical profile. Drugs Today (Barcelona), 40(8), 685–695.CrossRef
go back to reference Muhonen, L. H., Lonnqvist, J., Juva, K., & Alho, H. (2008). Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry, 69(3), 392–399.CrossRefPubMed Muhonen, L. H., Lonnqvist, J., Juva, K., & Alho, H. (2008). Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry, 69(3), 392–399.CrossRefPubMed
go back to reference Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., et al. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524.CrossRefPubMed Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., et al. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524.CrossRefPubMed
go back to reference Parsons, C. G., & Gilling, K. (2007). Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods in Molecular Biology, 403, 15–36.CrossRefPubMed Parsons, C. G., & Gilling, K. (2007). Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods in Molecular Biology, 403, 15–36.CrossRefPubMed
go back to reference Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., et al. (2008). Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of FMR1 KO mice. The Journal of Physiology, 587(Pt 4), 787–804.CrossRefPubMed Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., et al. (2008). Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of FMR1 KO mice. The Journal of Physiology, 587(Pt 4), 787–804.CrossRefPubMed
go back to reference Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine, 348(14), 1333–1341.CrossRefPubMed Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine, 348(14), 1333–1341.CrossRefPubMed
go back to reference Rogers, S. J., Wehner, D. E., & Hagerman, R. (2001). The behavioral phenotype in fragile X: Symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. Journal of Developmental and Behavioral Pediatrics, 22(6), 409–417.PubMed Rogers, S. J., Wehner, D. E., & Hagerman, R. (2001). The behavioral phenotype in fragile X: Symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. Journal of Developmental and Behavioral Pediatrics, 22(6), 409–417.PubMed
go back to reference SPSS Inc. (2005). SPSS 13.0 for windows. Chicago, IL: SPSS, Inc. SPSS Inc. (2005). SPSS 13.0 for windows. Chicago, IL: SPSS, Inc.
go back to reference Tervonen, T. A., Louhivuori, V., Sun, X., Hokkanen, M. E., Kratochwil, C. F., Zebryk, P., et al. (2008). Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiology of Disease, 33(2), 250–259.CrossRefPubMed Tervonen, T. A., Louhivuori, V., Sun, X., Hokkanen, M. E., Kratochwil, C. F., Zebryk, P., et al. (2008). Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiology of Disease, 33(2), 250–259.CrossRefPubMed
go back to reference Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., et al. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry, 163(1), 153–155.CrossRefPubMed Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., et al. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry, 163(1), 153–155.CrossRefPubMed
Metagegevens
Titel
Open-Label Memantine in Fragile X Syndrome
Auteurs
Craig A. Erickson
Jennifer E. Mullett
Christopher J. McDougle
Publicatiedatum
01-12-2009
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 12/2009
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-009-0807-3

Andere artikelen Uitgave 12/2009

Journal of Autism and Developmental Disorders 12/2009 Naar de uitgave